留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

林奇综合征相关子宫内膜癌研究进展

刘晓 李玉兰 马杏 许飞雪

刘晓, 李玉兰, 马杏, 许飞雪. 林奇综合征相关子宫内膜癌研究进展[J]. 协和医学杂志.
引用本文: 刘晓, 李玉兰, 马杏, 许飞雪. 林奇综合征相关子宫内膜癌研究进展[J]. 协和医学杂志.
LIU Xiao, LI Yulan, MA Xing, XU Feixue. Advances in the Study of Lynch Syndrome Associated Endometrial Cancer[J]. Medical Journal of Peking Union Medical College Hospital.
Citation: LIU Xiao, LI Yulan, MA Xing, XU Feixue. Advances in the Study of Lynch Syndrome Associated Endometrial Cancer[J]. Medical Journal of Peking Union Medical College Hospital.

林奇综合征相关子宫内膜癌研究进展

基金项目: 

甘肃省科技计划(21JR7RA378)

详细信息
    通讯作者:

    许飞雪,E-mail:xfx.sxq@163.com

Advances in the Study of Lynch Syndrome Associated Endometrial Cancer

Funds: 

Science and technology project of Gansu Province(21JR7RA378)

  • 摘要: 林奇综合征(Lynch syndrome,LS)是错配修复基因缺陷引起的常染色体显性遗传病,多系统恶性肿瘤易感是其主要特征,LS相关子宫内膜癌(LS associated endometrial cancer,LS-EC)是LS最常见的肠外前哨癌。精准医学时代,LS-EC的早期筛查对于预防LS相关其他恶性肿瘤的发生具有重要意义。本文就LS-EC的筛查手段及预防研究进展进行综述,以期为LS相关肿瘤患者精准诊疗及预防提供参考。
  • [1] Dörk T, Hillemanns P, Tempfer C, et al. Genetic Susceptibility to Endometrial Cancer:Risk Factors and Clinical Management[J]. Cancers (Basel),2020,12:2407.
    [2] Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer,2022,150:7-17.
    [3] Pastor DM, Schlom J. Immunology of Lynch Syndrome[J]. Curr Oncol Rep, 2021,23:96.
    [4] Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome[J]. Histopathology,2010,56:167-179.
    [5] Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome:a cohort study[J]. Lancet Oncol,2011,12:49-55.
    [6] Morak M, Ibisler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation[J]. J Med Genet, 2018,55:240-248.
    [7] Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants:findings from the Prospective Lynch Syndrome Database[J]. Genet Med,2020,22:15-25.
    [8] Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome:Implications for Stratified Surveillance Strategies[J]. JAMA Oncol,2017,3:1702-1706.
    [9] Staff S, Aaltonen M, Huhtala H, et al. Endometrial cancer risk factors among Lynch syndrome women:a retrospective cohort study[J]. Br J Cancer, 2016, 115:375-381.
    [10] Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC:a comparison with sporadic endometrial carcinoma[J]. Cancer,2006,106:87-94.
    [11] Rossi L, Le Frere-Belda MA, Laurent-Puig P, et al. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome:A French Multicenter Study[J]. Int J Gynecol Cancer,2017,27:953-960.
    [12] Ramchander NC, Ryan NAJ, Walker TDJ,et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer[J]. Front Immunol,2020,10:3023.
    [13] Bogani G, Tibiletti MG, Ricci MT, et al. Lynch syndrome-related non-endometrioid endometrial cancer:analysis of outcomes[J]. Int J Gynecol Cancer,2020,30:56-61.
    [14] Carr C, Son J, Yao M, et al. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening[J]. Gynecol Oncol,2020,159:712-720.
    [15] 杨子慧,刘新宇,杨曦,等.林奇综合征患者子宫内膜癌及卵巢癌的筛查与预防[J].国际妇产科学杂志,2021,48:453-456. Yang ZH, Liu XY, Yang X, et al. Screening and prevention of endometrial carcinoma and ovarian cancer in patients with Lynch syndrome[J]. Guoji Fuchanke Zazhi,2021

    ,48:453-456.
    [16] Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1[J]. Gastroenterology, 2005,129:537-549.
    [17] Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors[J]. Cancers (Basel),2021,13:467.
    [18] Dietmaier W, Wallinger S, Bocker T, et al. Diagnostic microsatellite instability:definition and correlation with mismatch repair protein expression[J]. Cancer Res,1997,57:4749-56.
    [19] Houlleberghs H, Dekker M, Lusseveld J, et al. Three-step site-directed mutagenesis screen identifies pathogenic MLH1 variants associated with Lynch syndrome[J]. J Med Genet,2020,57:308-315.
    [20] Gallon R, Gawthorpe P, Phelps RL, et al. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies[J]. Cancers (Basel),2021,13:406.
    [21] Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383:2053-2064.
    [22] Van den Heerik ASVM, Horeweg N, De Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification:radiotherapy, chemoradiation and novel targets for therapy[J]. Int J Gynecol Cancer,2021,31:594-604.
    [23] Gompel A. Progesterone and endometrial cancer[J]. Best Pract Res Clin Obstet Gynaecol,2020,69:95-107.
    [24] Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med,2015,372:2509-2520.
    [25] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer:Results From the Phase II KEYNOTE-158 Study[J]. J Clin Oncol,2020,38:1-10.
    [26] Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study:a double-blind, randomised, placebo-controlled trial[J]. Lancet,2020,395:1855-1863.
    [27] Seppälä TT, Dominguez-Valentin M, Crosbie EJ, et al. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants:a Prospective Lynch Syndrome Database report[J]. Eur J Cancer,2021,148:124-133.
    [28] Crosbie EJ, Ryan NAJ, Arends MJ, et al. Manchester International Consensus Group, Evans DG. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome[J]. Genet Med,2019,21:2390-2400.
    [29] Roudko V, Cimen Bozkus C, Greenbaum B, et al. Lynch Syndrome and MSI-H Cancers:From Mechanisms to "Off-The-Shelf" Cancer Vaccines[J]. Front Immunol,2021,12:757804.
    [30] Bayó C, Jung G, Español-Rego M, et al. Vaccines for Non-Viral Cancer Prevention[J]. Int J Mol Sci,2021,22:10900.
  • 加载中
计量
  • 文章访问数:  21
  • HTML全文浏览量:  5
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-07
  • 网络出版日期:  2022-06-01

目录

    /

    返回文章
    返回